Cogent Biosciences Announces Multiple Presentations at the 67th Annual American Society of Hematology (ASH) Meeting

Core Insights - Cogent Biosciences, Inc. announced multiple presentations for bezuclastinib at the upcoming 67th Annual Meeting of the American Society of Hematology (ASH), highlighting its potential as a best-in-class treatment for NonAdvanced Systemic Mastocytosis (NonAdvSM) [1][2] - The company is also set to present a novel JAK2 V617F mutant-selective inhibitor, which is expected to be on track for an Investigational New Drug (IND) application in 2026 [1][2] Presentation Details - Bezuclastinib will be featured in two oral presentations at ASH, focusing on its efficacy and safety results from the pivotal Summit trial in adults with NonAdvSM [3] - The first oral presentation will take place on December 6, 2025, at 9:45 AM ET, presented by Dr. Lindsay Rein [3] - The second oral presentation will discuss the effects of bezuclastinib on mastocytosis pathobiology, scheduled for December 8, 2025, at 5:00 PM ET, presented by Dr. Tracy George [4] Additional Research - A poster presentation will explore the relationship between KIT inhibition by bezuclastinib and its effects on disease burden in mouse models of systemic mastocytosis, scheduled for December 8, 2025 [5] - Preclinical data on the novel JAK2 V617F mutant-selective inhibitor will also be presented in a poster session on December 7, 2025 [6] Company Overview - Cogent Biosciences focuses on developing precision therapies for genetically defined diseases, with bezuclastinib being a selective tyrosine kinase inhibitor targeting the KIT D816V mutation, which drives systemic mastocytosis [7] - The company is also developing a portfolio of targeted therapies aimed at various mutations, including FGFR2/3, ErbB2, PI3Kα, KRAS, and JAK2 [7]